Table 2.
Base Case Results
| Result | First-Line Model |
Second-Line Model |
||||
|---|---|---|---|---|---|---|
| FOLFOX | FOLFOX Plus Bevacizumab | Incremental | FOLFIRI | FOLFIRI Plus Bevacizumab | Incremental | |
| LYs | 1.78 | 1.92 | 0.14 | 0.99 | 1.15 | 0.16 |
| QALYs | 1.31 | 1.41 | 0.10 | 0.64 | 0.75 | 0.11 |
| Total cost of regimen, $* | 32,561 | 93,112 | 60,551 | 7,443 | 46,764 | 39,321 |
| ICER, $ | ||||||
| Per LY | 438,779 | 235,455 | ||||
| Per QALY | 571,240 | 364,083 | ||||
Abbreviations: FOLFIRI, fluorouracil plus irinotecan; FOLFOX, fluorouracil plus oxaliplatin; ICER, incremental cost-effectiveness ratio; LY, life-year; QALY, quality-adjusted life-year.
*
Total cost of regimen in first-line model = first-line chemotherapy + second-line chemotherapy + adverse events. Total cost of regimen in second-line model = second-line chemotherapy + adverse events.